Pro-Optics LLC – FDA Warning Letter, Mar 11, 2026

Pro-Optics, LLC received a formal Warning Letter from the FDA following an inspection of its Palatine, Illinois facility conducted between March 3 and March 11, 2026. The agency identified significant regulatory violations concerning the company’s Tight Top and Flip Top contact lens cases. The primary issue involves the sale of unapproved medical devices. Pro-Optics implemented significant modifications to the materials and chemical compositions of its products—specifically changing polymers and adding eight unauthorized colorants—without submitting the required premarket notifications (510(k)). Because these changes introduce unreviewed risks to safety and biocompatibility, the devices are legally classified as adulterated and misbranded under the Federal Food, Drug, and Cosmetic Act. Furthermore, the inspection uncovered substantial failures in the company"s Quality Management System (QMS). Pro-Optics failed to maintain documented procedures for product design and development as required by federal regulations (21 CFR Part 820) and ISO standards. Specifically, the firm lacked records for design transfers, technical drawings, and impact assessments after switching manufacturing processes and suppliers. The FDA has directed Pro-Optics to submit a written response within 15 business days detailing the specific corrective actions taken to address these systemic failures. The company must provide a comprehensive plan and implementation timetable to prevent future recurrence. Failure to resolve these issues promptly may result in further regulatory action, including product seizures or civil penalties.